# Safety and Efficacy of PegIntron and Rebetol Combination Therapy in Patients With Chronic Hepatitis C in Japan (Study P04505)

> **NCT00724295** · — · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1077 (actual)

## Conditions studied

- Hepatitis C, Chronic
- Hepatitis C

## Interventions

- **DRUG:** peginterferon alfa-2b
- **DRUG:** ribavirin

## Key facts

- **NCT ID:** NCT00724295
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 1077 (ACTUAL)
- **Last updated:** 2015-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00724295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00724295, "Safety and Efficacy of PegIntron and Rebetol Combination Therapy in Patients With Chronic Hepatitis C in Japan (Study P04505)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00724295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*